Many cardio-oncology patients at increased risk for congestive heart failure from cancer therapy have OSA. Completing HBOT appears effective at reducing pain and fibrosis in patients with irradiated breast cancer. What does the data and overall understanding of VEGF-TKIs tell us about which patients are optimal candidates for tivozanib? Dr. Jacob Hall joins The Fellow on Call group to discuss patient selection for radiation therapy for prostate cancer. A researcher is looking to prove that nebivolol, an FDA-approved drug for high blood pressure, is effective at treating TNBC. Dr. Salma Jabbour joins Dr. Chadi Nabhan to provide her invaluable perspective on the PROSPECT trial findings. Dr. Sanjay Patel joins The Fellow on Call team to discuss prostate cancer from the perspective of a urologist. LSU LCMC Health Cancer Center has been awarded a $1.5 million grant to help combat barriers to cervical cancer prevention. Screening and new treatments have led to a US breast cancer mortality rate that is 58% lower than in it was in the mid-1970s. The FDA recently approved a new combination therapy for the treatment of HR-positive, HER2-negative breast cancer. DermaSensor announced this week that the US FDA cleared its AI-based handheld device for detecting skin cancer. City of Hope and COG conducted a clinical trial with the goal of reducing HF risk in childhood cancer survivors. According to a retrospective study, a high preoperative CONUT score indicates poor prognosis in cervical cancer. CNS radiotherapy with pyrotinib and capecitabine improves CNS progression in breast cancer patients with brain metastases. The Oncology Brothers talk with Paolo Tarantino, MD, about the TROPiCS-02 study presented at SABCS. The Fellow on Call team provides a nuanced overview of the individual chemotherapy agents used in the clinical setting. Dr. Chadi Nabhan and experts discuss the intricate relationship between the microbiome and cancer. Will HER2CLIMB-02 study data impact the breast cancer landscape? A noninvasive magnetic resonance imaging technique can effectively evaluate bone marrow in patients with myelofibrosis. CALR-1 mutation is an important risk factor for both drug survival and longevity in momelotinib-treated patients with MF.